[{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Inapplicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Inapplicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"San Fu Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RGI-2001","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ San Fu Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ San Fu Biotech"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Burixafor Hydrobromide","moa":"CXCL-12\/CXCR-4","graph1":"Immunology","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Biotechnology \/ GPCR Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the terms of agreement, REGiMMUNE and SFB will collaborate closely to accelerate the development of RGI-2001 (alpha galactosylceramide liposomal), a first-in-class small molecule drug candidate, in major Asian countries for the prophylaxis of aGvHD...

                          Product Name : RGI-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 29, 2023

                          Lead Product(s) : RGI-2001

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : San Fu Biotech

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT).

                          Product Name : RGI-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2022

                          Lead Product(s) : RGI-2001

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT).

                          Product Name : RGI-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2022

                          Lead Product(s) : RGI-2001

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : UB-221 shows 2 to 5-folds inhibition of IgE synthesis than Xolair in the in vitro study. UB-221 only takes 1/10 dose to achieve the same effect of Xolair in huIGHE-knock-in mice model. PK study in cynomolgus monkeys demonstrated UB-221 has a longer serum...

                          Product Name : UB-221

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 27, 2022

                          Lead Product(s) : UB-221

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases.

                          Product Name : UB-221

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 08, 2022

                          Lead Product(s) : UB-221

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.

                          Product Name : TG-0054

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 11, 2020

                          Lead Product(s) : Burixafor Hydrobromide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : GPCR Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank